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ABSTRACT 
Background: Evidence from observational studies of telomere length (TL) has been conflicting 
regarding its direction of association with cancer risk. We investigated the causal relevance of TL 
for lung and head and neck cancers using Mendelian Randomization (MR) and mediation analyses. 
Methods: We developed a novel genetic instrument for TL in chromosome 5p15.33, using variants 
identified through deep-sequencing, that were genotyped in 2051 cancer-free subjects. Next, we 
conducted an MR analysis of lung (16396 cases, 13013 controls) and head and neck cancer (4415 
cases, 5013 controls) using 8 genetic instruments for TL. Lastly, the 5p15.33 instrument and distinct 
5p15.33 lung cancer risk loci were evaluated using two-sample mediation analysis, to quantify their 
direct and indirect, telomere-mediated, effects. 
Results: The multi-allelic 5p15.33 instrument explained 1.49-2.00% of TL variation in our data 
(p=2.6×10
-9
). The MR analysis estimated that a 1000 base pair increase in TL increases risk of lung 
cancer (OR=1.41, 95% CI: 1.20-1.65) and lung adenocarcinoma (OR=1.92, 95% CI: 1.51-2.22), but 
not squamous lung carcinoma (OR=1.04, 95% CI: 0.83-1.29), or head and neck cancers (OR=0.90, 
95% CI: 0.70-1.05).  Mediation analysis of the 5p15.33 instrument indicated an absence of direct 
effects on lung cancer risk (OR=1.00, 95% CI: 0.95-1.04). Analysis of distinct 5p15.33 susceptibility 
variants estimated that TL mediates up to 40% of the observed associations with lung cancer risk.  
Conclusions: Our findings support a causal role for long telomeres in lung cancer etiology, 
particularly for adenocarcinoma, and demonstrate that telomere maintenance partially mediates the 
lung cancer susceptibility conferred by 5p15.33 loci.  
  
Page 6 of 38
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 5
KEY MESSAGES 
• Genetic predisposition to long telomeres increases risk of lung cancer, predominately lung 
adenocarcinoma  
• Genetic determinants of long telomeres are not associated with squamous carcinomas of 
the lung or head and neck 
• Using two-sample mediation analysis we determined that the novel 5p15.33 instrument for 
telomere length does not have direct effects on the outcome, and demonstrated that the 
association between 5p15.33 lung cancer susceptibility variants is partially mediated by 
telomere length, suggesting the presence of other relevant mechanisms  
Page 7 of 38
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 6
INTRODUCTION 
Telomeres are highly conserved stretches of tandem repeats of the TTAGGG sequence, 
which protect chromosome ends from degradation and maintain genome stability(1, 2). Due to the 
incomplete replication of chromosomes during cell division, human telomeres lose between 50 and 
200 base pairs with each replication(1-3). In checkpoint proficient cells critically short telomeres 
trigger senescence, followed by apoptosis, which represents a barrier against cancer initiation by 
limiting cellular proliferation(4, 5). As telomeres shorten their ability to maintain chromosomal 
stability also diminishes, which may increase cancer susceptibility(6, 7). However, long telomeres 
may also promote cancer development through an accumulation of mutations due to prolonged cell 
survival and proliferation. In fact, cancer cells are characterized by such a proliferative advantage, 
often through reactivation of telomerase, which is normally silent in somatic cells(4, 5, 8).  
Telomere length (TL) has been studied extensively in relation to cancer risk. However, 
findings of epidemiologic studies have been conflicting (6, 9-11). Observational studies investigating 
TL measured after cancer diagnosis are particularly vulnerable to reverse causation and residual 
confounding, therefore shorter TL observed in cancer cases is likely to reflect underlying disease or 
the impact of cancer treatment (12, 13). It is also difficult to isolate the influence of TL on cancer risk 
from that of other risk factors that influence both TL and cancer susceptibility, including biological or 
replicative age (10, 14, 15).  
Mendelian Randomization (MR) is an approach for evaluating causality by using single 
nucleotide polymorphisms (SNPs) in relevant genes as instrumental variables (IVs) (16). Genome-
wide association studies (GWAS) identified a number of genetic regions involved in TL regulation, 
including genes encoding the catalytic subunit of telomerase (TERT) in chromosome 5p15.33 and 
its RNA template (TERC) in 3q26.2 (17-21). By leveraging these associations, MR can provide a 
valid test of the causal hypothesis assuming the genetic IVs only affect cancer risk through TL 
regulation. 
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Previous studies using genetic proxies for TL suggest that longer telomeres confer an 
increased risk of lung cancer, especially adenocarcinoma (22-24), which is consistent with the 
findings of prospective observational studies (25-27). Lung cancer case-control studies report both 
increased (28) and inverse (6, 29) associations for long TL, and some implicate high TL variability in 
lung cancer susceptibility (30). For head and neck cancers (HNC), which are predominantly 
squamous carcinomas, short TL is consistently associated with increased risk in case-control 
studies (6, 31, 32), whereas a recent MR analysis (24) did find evidence supporting a causal 
relationship.  
The overarching aim of this study is to investigate the causal relationship between TL and 
risk of lung and upper aero-digestive tract cancers. First, we developed a novel genetic instrument 
for TL in chromosome 5p15.33, given the extensive pleiotropy in this region and potential for 
violating MR assumptions (22, 33). Next, we conducted the largest two-sample MR analysis of lung 
and HNC risk to date. Lastly, we quantified the direct and telomere-mediated effects of 5p15.33 
genetic variants on cancer risk using a two-sample mediation analysis approach (Figure 1).  
METHODS 
Study populations 
We used individual-level data from 23 pooled studies of lung cancer, with 16396 cases 
(5690 adenocarcinoma, 4045 squamous carcinoma) and 13013 controls; and 11 HNC studies with 
4415 cases and 5013 controls, all part of the OncoArray collaboration (34) (Supplementary Tables 
1-2). Descriptions of studies and genotyping methods have been previously published (34, 35) 
(details in Supplementary File 1). Analyses were restricted to individuals of predominantly European 
ancestry (≥80% lung, >70% HNC)(34, 36). Studies received approval from institutional research 
ethics review boards and informed consent was obtained from the participants.  
The novel 5p15.33 instrument was developed using data from two studies: the cancer-free 
controls from the Mount Sinai and Princess Margaret Hospital (MSH-PMH) case-control study in 
Toronto(37), and cancer-free individuals from the Copenhagen General Population Study 
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(CGPS)(38), a population-based prospective cohort (Table 1). TL was measured in DNA from 
peripheral blood leukocytes using previously described quantitative polymerase chain reaction 
assays performed in MSH-PMH (37) and CGPS (23, 38) (details in Supplementary File 2). 
Statistical Analysis 
Mendelian randomization analysis 
 The genetic instruments for TL included independent SNPs showing strong prior evidence 
of association with TL, such as p<5×10
-8
 in the discovery stage of at least one GWAS and 
replication in a separate GWAS or meta-analysis (17-21). In addition to the new 5p15.33 instrument 
described below, we selected 7 additional loci involved in telomere maintenance: rs10165485 
(proxy for rs11125529, r
2
=1.0) in ACYP2 (2p16.2), rs6772228 in PXK (3p14.3), rs10936599 in 
TERC (3q26.2), rs11100479 (proxy for rs7675998, r
2
=0.99) in NAF1 (4q32.2), rs9420907 in OBFC1 
(10q24.3), rs10419926 in ZNF676 (19p12), and rs755017 near RTEL1 and ZBTB46 (20q13).  Only 
genotyped, non-imputed variants were used. 
For the purpose of developing a new instrument in the 5p15.33 region, TL values were 
converted to Z-scores in MSH-PMH (n=879) and CGPS (n=1172) studies separately, and pooled to 
increase statistical power. Linear regression was used to estimate the association between 899 
variants in 5p15.33 and TL, adjusting for age, sex, study, and the top 5 genetic ancestry principal 
components (PCs).  
Selection of variants for the 5p15.33 instrument was based on statistical significance, 
consistency across the two studies, and instrument strength, measured by the F statistic, which 
depends on the variance in TL explained by the genetic predictors (R
2
), sample size (n), and 
number of instruments (k): . Variants were considered for inclusion in the 
5p15.33 instrument if they met the following criteria: 
i. F≥5 and p<0.05 in the Toronto and Copenhagen combined dataset (n=2051) 
F =
n− k −1
k






R
2
1−R2






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ii. F<5 and p<0.05 overall (n=2051) and F>5 among never smokers (n=848) 
iii. Consistent direction of allelic effects in MSH-PMH and CGPS 
iv. Minor allele detected in at least 2 individuals 
Independent genetic variants (r
2
<0.2) that met the selection criteria were combined into an allele 
score representing the 5p15.33 region to increase the power of the resulting instrument (39, 40). 
The MR analysis combined summary statistics across the genetic IVs to estimate the 
causal parameter , which is the log odds ratio (OR) describing the causal effect of increasing TL 
on cancer risk (Supplementary Figure 1).  Parameters for the MR analysis included  and , 
where  is a vector of SNP-TL associations and is a vector of per-allele cancer log ORs for 
each instrument. For genetic instruments outside of 5p15.33, and corresponding standard errors 
(SE) were obtained from the literature and scaled to represent a 1000 base pair (kbp) increase in 
leukocyte TL, a proxy for TL in relevant tissues(19-21). For all instruments, and corresponding 
SE were estimated directly using individual-level OncoArray lung and HNC data. Logistic regression 
models were adjusted for age, sex, study, and 10 PCs. 
The causal parameter  was estimated using the maximum likelihood-based (ML) 
approach and the inverse-variance weighted (IVW) method (41, 42). This was complemented by 
sensitivity analyses using the weighted median estimator (WME), which provides valid estimates of 
the causal parameter even when up to 50% of the statistical weights are contributed by genetic 
instruments violate MR assumptions (43).  
Mediation analysis 
The aim of the mediation analysis was to quantify how much of the lung cancer association 
in the 5p15.33 region is mediated by TL. First, we validated the 5p15.33 instrument by 
decomposing its total effect on lung cancer into direct and indirect effects, mediated by TL. Next, we 
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extended this analysis to independent (r
2
<0.20) variants that capture the lung cancer association 
signal in 5p15.33 (details in Supplementary File 3).  
Our mediation approach is based on the counterfactual framework(44, 45) and extends the 
sensitivity analysis using two randomized controlled trials proposed by Vanderweele, which allows 
the mediator-outcome ( ) and exposure-mediator ( ) relationships to be estimated in separate 
studies (46). Application of this approach in the present context assumes that a valid estimate for 
the mediator-outcome relationship can be obtained from an independent MR or cohort studies. 
Based on previously published formulas for mediation analysis (44, 45), the total effect (TE) of 
increasing the exposure from reference level a
*
 to level a on lung cancer ( ) conditional on 
covariates c can be decomposed into natural direct effects (NDE) and natural indirect effects (NIE): 
 
Assuming a rare outcome and absence of exposure-mediator interaction, mediated effects are 
given by: 
 
where is log-OR per one unit increment in TL and is the effect of the 5p15.33 instrument on 
TL. Based on equation 1, NDE can be obtained by subtracting the NIE from the total effect: 
 
In the presence of interaction between the exposure and mediator, the NIE is given by: 
 
where now represents the main effect of the mediator, TL, and  is the exposure-mediator 
interaction parameter, with NDE having a more complicated form given by Valeri and 
VanderWeele(45). Formulas for a dichotomized mediator are provided in Supplementary File 4. 
θ
2
β
1
OR
a,a*|c
TE =
P(Y
a
=1| c) /{1− P(Y
a
=1| c)
P(Y
a*
=1| c) /{1− P(Y
a*
=1| c)
=OR
a,a*|c
NIE ×OR
a,a*|c
NDE (1)
OR
a,a*|c
NIE ≈ exp{θ
2
×β
1
(a− a*)} (2)
θ
2
β
1
log(OR
a,a*|c
NDE ) ≈ log(OR
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TE )− log(OR
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The  parameter for the 5p15.33 instrument is equivalent to  estimated in the cancer-
free subset of the MSH-PMH and CGPS studies, adjusting for appropriate covariates. For 5p15.33 
cancer susceptibility variants, estimates were selected from Bojesen et al. (47), the largest fine-
mapping analysis of common 5p15.33 loci and TL with 15567 cancer-free controls. Per allele 
associations were reported as percent increase in TL and base-pair change. OR
TE
 for all variants 
was estimated in 23 lung cancer OncoArray studies, and is equivalent to for the 5p15.33 
instrument.  
External estimates of the mediator-outcome relationship ( ) were substituted into the 
equation (2) to avoid estimating the effect of TL on lung cancer risk directly using MSH-PMH case-
control data, which are likely to be biased due to the post-diagnostic timing of TL measurement. 
The effect of TL on lung cancer risk was obtained from two studies: an MR analysis TL by Zhang et 
al.(22), and a meta-analysis of prospective studies by Zhu et al. (11) (Supplementary Figure 2).  
Since interaction between the 5p15.33 instrument and TL is plausible, we conducted 
sensitivity analyses under different magnitudes of 
 
(details in Supplementary File 4). Confidence 
intervals for the NIE and NDE were approximated as Bayesian credible intervals. Analyses were 
conducted using R version 3.3.3. 
RESULTS 
Characteristics of the combined Toronto and Copenhagen dataset (n=2051), used to 
develop the 5p15.33 instrument, are summarized in Table 1. The cancer-free participants in the 
MSH-PMH and CGPS studies were of similar mean age, 61.0 and 61.30 years, respectively. Age 
was the strongest predictor of TL (p=2.6×10
-30
), while sex, smoking status, and cigarette pack-years 
among smokers were not associated with relative TL (Supplementary Table 3).  
Novel 5p15.33 instrument for telomere length 
The 5p15.33 variants comprising this instrument were not used in any previous MR studies 
of TL. After excluding 17 singletons and other SNPs that did not meet our criteria, 14 variants were 
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included in the multi-allelic instrument for 5p15.33 (Table 2; regional plot and LD illustrated in 
Supplementary Figure 3). Most variants were located in non-coding intronic regions of several 
genes, including SLC6A3, TERT, LPCAT1, and a long-noncoding RNA (LINC01511) except for 
rs35033501, a synonymous TERT variant. The resulting multi-allelic 5p15.33 IV accounted for 
1.49% of variation in the telomere Z-score in all subjects (F = 35.83; = 0.14, SE=0.02) and 
2.00% in never smokers (F = 20.81), but was not predictive of smoking status (p=0.19) or cigarette 
pack-years among smokers (p=0.59) (Table 3). The 5p15.33 instrument was positively associated 
with lung cancer (OR=1.04, 95% CI: 1.01-1.07) and lung adenocarcinoma (OR=1.06, 1.03-1.10), 
but not squamous lung carcinomas (OR=1.03, 0.98-1.07). An inverse association was observed for 
HNC (OR=0.95, 0.90-1.00) and oral cavity cancer (OR=0.93, 0.87-0.98). 
Telomere length and cancer risk 
Results of the MR analysis based on 8 genetic instruments are presented in Table 4 and 
Figure 2. The likelihood-based model estimated a 41% increase in lung cancer risk per kbp 
increase in TL (ORML=1.41, 95% CI: 1.20-1.65). Estimates of the causal OR for lung cancer 
remained consistent across MR estimation methods. Genetic determinants of TL were 
predominantly associated with adenocarcinoma (ORML=1.92, 1.51-2.45), and appeared unrelated to 
squamous carcinoma (ORML=1.04, 0.83-1.29) and small cell carcinoma (ORML=1.03, 0.76-1.39). 
The effect of long TL on lung cancer risk was larger in magnitude among never smokers  
(ORML=1.78, 1.22-2.61) compared to smokers (ORML=1.36, 1.14-1.63), although the former was 
attenuated in sensitivity analyses (ORWME=1.55, 95% CI: 0.98-2.46). Effects on adenocarcinoma 
risk were also substantial in never smokers (ORML=2.68, 1.70-4.24). Genetic determinants of long 
telomeres conferred a 68% increase in lung cancer risk (ORML=1.68, 1.07-2.62) in subjects aged 50 
years or younger. In contrast to lung cancer, genetic predisposition for longer TL did not seem 
related to risk of HNC overall (ORML= 0.90, 0.70-1.05), oral cavity (ORML=0.88, 0.65-1.19) and 
oropharynx cancers (ORML=0.83, 0.59-1.16).  
β
TL
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Several additional sensitivity analyses were undertaken to further interrogate the MR 
results. Since smoking is an established risk factor for both HNC and lung cancer, MR analyses 
were repeated with adjustment for cigarette pack-years and smoking status. No appreciable 
changes were observed in the causal effect estimates for lung cancer overall (ORML=1.50, 1.27-
1.78), lung adenocarcinoma (ORML=1.95, 1.53-2.49), HNC (ORML=0.91, 0.67-1.23), oral cavity 
(ORML=0.82, 0.57-1.18) or oropharynx cancers (ORML=0.86, 0.57-1.31).  
The potential for directional pleiotropy was evaluated by checking for asymmetry in the 
plots depicting ratio estimates for each instrument, , plotted against instrument strength, 
 (Supplementary Figure 4). These results were not suggestive of pleiotropy and none of 
the genetic instruments we e associated with cigarette smoking status or pack-years 
(Supplementary Table 4). Lastly, selected causal effects were re-estimated using the weighted 
mode-based estimator (MBE), which is robust to horizontal pleiotropy when the largest number of 
similar causal effect estimates are based on valid instruments, even if the majority of instruments 
are invalid (48). Estimates for lung cancer overall (ORMBE=1.34, 1.08-1.66), lung adenocarcinoma 
(ORMBE=1.55, 1.14-2.12), and adenocarcinoma in never smokers (ORMBE=2.04, 1.04-4.04), were 
consistent with the primary results in Table 4. 
Mediation analysis of the 5p15.33 instrument 
We conducted mediation analyses to quantify direct (OR
NDE
) and indirect effects (OR
NIE
) of 
the 5p15.33 instrument on lung cancer. The OR
NIE
 we report is the proportional change in the odds 
of lung cancer for a change in TL that occurs when the 5p15.33 allele score increases by one from 
the reference level, corresponding to the mean of the allele score distribution. The estimate of the 
TL effect on lung cancer ( ) was selected from the strict model reported by Zhang et al.(22) (OR 
per kbp increase: 1.37, 95% CI: 1.12-1.68), which excluded rs2736100 (TERT). OR
TE
 for the 
5p15.33 IV was re-estimated after removing overlapping subjects (n=3498) between the OncoArray 
and Zhang et al.(22). Assuming no interaction between the 5p15.33 IV and TL, the lung cancer 
effect appeared to be almost entirely mediated by TL (OR
NIE
=1.05, 1.01-1.08), whereas the direct 
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effects of the 5p15.33 IV appeared null (OR
NDE
=1.00, 0.95-1.04) (Figure 3; Supplementary Table 5). 
For lung adenocarcinoma, the 5p15.33 effects mediated by TL were larger in magnitude 
(OR
NIE
=1.11, 1.05-1.18) than direct effects, which were close to unity (OR
NDE
=0.97, 0.90-1.03). 
Interaction sensitivity analyses for the NIE and NDE were carried out across three levels of 
: 0.10, 0.20 and 0.30. As the magnitude of the interaction parameter increased, so did the NIE, 
while TL-independent effects were not observed (Figure 3). Indirect effects on lung cancer risk 
mediated by TL ranged from OR
NIE
=1.06 (95% CI: 1.03-1.10) for =0.10, to OR
NIE
=1.09 (95% CI: 
1.05-1.15) for = 0.30. For adenocarcinoma, increasing the magnitude of interaction between the 
5p15.33 IV and TL was also associated with increasing NIE and diminishing direct effects. 
The prospective meta-analysis estimate of from Zhu et al.(11) reported an OR of 1.28 
(95% CI: 1.09-1.50) for lung cancer comparing long vs. short TL. Based on this binary mediator, the 
NIE mediated by TL was attenuated, but remained statistically significant (OR
NIE
=1.01, 1.00-1.03). A 
positive direct effect on lung cancer risk was also observed (OR
NDE
=1.03, 1.00-1.06). Assuming 
interaction between the 5p15.33 instrument and TL, the mediated effects ranged from OR
NIE
=1.02 
(95% CI: 1.01-1.03) when =0.10, to OR
NIE
=1.03 (95% CI: 1.01-1.05) when =0.30, while the 
direct effects decreased (Figure 3; Supplementary Table 5). 
Mediation analysis of 5p15.33 lung cancer susceptibility loci 
Five common (MAF>0.05), independent (r
2
 <0.20) variants were selected to represent the 
lung cancer susceptibility signal in 5p15.33 (details in Supplementary File 3): rs7705526 
(PAdeno=4.6×10
-13
; PLung=8.0×10
-7
), rs2736108 (PAdeno=1.7×10
-12
; PLung=1.8×10
-11
), rs421629 
(PAdeno=6.2×10
-9
; PLung=1.2×10
-16
), rs13167280 (PAdeno=1.4×10
-8
; PLung=1.1×10
-6
), and rs56345976 
(PAdeno=2.2×10
-7
; PLung=3.6×10
-9
). These variants have been associated with lung cancer and lung 
adenocarcinoma in previous studies (37, 49-51), and are representative of the genetic susceptibility 
architecture in this region.  
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Estimates of  were obtained from Bojesen et al.(47), and three TERT lung cancer risk 
variants were significantly associated with TL: rs7705526 (PTL=2.3×10
-14), rs2736108 (PTL=5.8×10
-7), 
and rs13167280 (PTL=1.2×10
-5). Estimates of were selected from the MR analysis (22) and OR
TE
 
were re-estimated for each variant after removing the overlapping subjects. For all variants, the TL-
increasing allele was positively associated with cancer risk, and both direct and indirect, TL-
mediated effects were significant (Supplementary Table 6).  
For lung cancer, the proportion mediated (PM) by TL was the largest for rs13167280 
(OR
NIE
=1.05, 1.03-1.07; PM=40.5%), followed by rs7705526 (OR
NIE
=1.03, 1.01-1.05; PM=28.7%) 
and rs2736108 (OR
NIE
 1.02, 1.01-1.03; PM=13.7%). The magnitude and proportion of the SNP 
effects that were mediated by TL were larger for adenocarcinoma compared to lung cancer overall: 
rs7705526 (OR
NIE
=1.07, 1.04-1.10; PM=36.5%), rs13167280 (OR
NIE
=1.05, 1.03-1.07; PM=24.8%), 
and rs2736108 (OR
NIE
=1.04, 1.03-1.06; PM=22.9%). 
DISCUSSION 
We observed an association between genetic determinants of long telomeres and 
increased risk of lung, but not head and neck cancers. Our findings lend support to a causal 
relationship between longer leukocyte TL and increased risk of lung adenocarcinoma, but not 
squamous or small cell carcinoma. The magnitude of the increased risk was larger in never 
smokers and participants aged 50 or younger, consistent with a stronger influence of genetic 
susceptibility in individuals with a lower burden of modifiable risk factors (52). Although histology 
and smoking status are closely linked, our results suggest that the associations were histology-
specific for adenocarcinoma (53, 54). Lastly, our mediation analysis demonstrated that mechanisms 
resulting in long telomeres mediate a proportion of the increase in lung cancer and lung 
adenocarcinoma risk conferred by 5p15.33 loci, and that the proportion of genetic susceptibility 
attributed to telomere maintenance differs between distinct 5p15.33 susceptibility loci. 
Other analyses using multi-SNP telomere scores have also observed excess risks of lung 
cancer(22-24) and lung adenocarcinoma(22, 24), but did not observe an effect of TL on oral cancer 
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risk (23, 24). Opposite directions of effect for the 5p15.33 instrument on lung and HNC are 
consistent with earlier reports of opposing allelic effects for 5p15.33 SNPs on lung and oral cancer, 
respectively (35, 55). Leukocyte TL and functional TERT variants were previously reported to be 
unrelated to squamous HNC risk(56), although one study linked short TL to increased HNC risk 
based on rs2736100, which may be an invalid instrument(22, 57). With the exception of the 5p15.33 
IV, the instruments used in this study overlap with those used in other MR analyses of TL (22-24). 
Our findings lend support to the hypothesis that a greater number of telomere-increasing 
alleles increase lung cancer susceptibility. Although the precise molecular mechanisms remain to 
be elucidated, telomere maintenance may promote carcinogenesis by enabling prolonged cell 
survival and accumulation of mutations. This is supported by the hallmark observation that 
telomerase is overexpressed in 85-90% of adult tumors(8, 58), as well as recent data showing that 
long telomeres increase chromosomal instability(59) and promote immortalization of cancer 
cells(60). Excessively long telomeres may also be more fragile and dysfunctional, which is 
supported by the observation that TERT not only replenishes telomeres, but also regulates a 
trimming process to maintain TL homeostasis (61-63).   
Differences in the effect of TL persisted after stratifying by smoking status, suggesting that 
underlying mechanisms differ across tissues and histological types. Longer TL does not appear to 
increase risk of small cell lung cancer or squamous lung carcinoma, the histology that also 
comprises 90% of HNC tumours, and for which the causal effect of tobacco smoking is the 
strongest(64). Since our genetic instruments are unrelated to smoking, confounding is unlikely to 
account for these differences. It is plausible that genetic predisposition for telomere maintenance 
offers some protection against genomic instability due to oxidative stress, declining regenerative 
capacity and immune function(7, 65, 66). Although human papillomavirus (HPV), a known cause of 
oropharynx cancer(67), has been reported to correlate with TL(31), the similarity of associations 
observed for oropharynx and oral cancers, only 2% of which are attributed to HPV(68), suggests 
that HPV infection is unlikely to modify the influence of TL.  
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This analysis has several important strengths. Genetic instruments represent are 
unaffected by reverse causality and are more likely to reflect causality due to the independence of 
genotypes from confounding factors. In addition to the large sample size, our analysis leveraged 
rich genetic data in 5p15.33, including rare sequence variations, to develop a robust, novel 
instrument. Furthermore, the use of multiple genetic instruments from essential genes for telomere 
maintenance mitigates the possibility for weak instruments bias and genetic confounding due to 
pleiotropy. The association between genetic predisposition to long TL and increased lung cancer 
risk persisted in analyses using the weighted median and mode-based estimators, which further 
supports the causal interpretation of these results. 
Our mediation analysis offers insight not only by validating the new 5p15.33 instrument, by 
demonstrating an absence of direct effects, but also by formally quantifying the contribution of 
telomere-related mechanisms to the observed association between the established lung and 
adenocarcinoma susceptibility loci and lung cancer risk in this region. Although we confirmed that 
TL is an important molecular mechanism underlying the associations observed for 5p15.33 lung 
cancer risk loci, our results also indicated that only a fraction of these genetic effects operate 
through telomere maintenance. For instance, only 3-8% of the total effect of rs421629 (CLPTM1L) 
was mediated TL, and approximately half of the association between the TERT loci and lung cancer 
risk can be attributed to telomere mechanisms.  
These findings are consistent with our knowledge that 5p15.33 is a complex susceptibility 
locus for multiple cancers(33, 55, 69) and GWAS peaks in this region also encompass non-cancer 
traits, such as red blood cell counts, prostate-specific antigen levels, and lung diseases(69-72). In 
addition, non-canonical functions of TERT, related to proliferation and differentiation via regulation 
of Wnt/β-catenin and Myc signaling, have been proposed(73). Therefore, although telomere 
maintenance is clearly an important 5p15.33 mechanism, cancer susceptibility loci in this region 
likely invoke additional pathways. 
Several limitations of this work should be acknowledged. The time lag between genotype 
assignment at conception and the assessment of genetic effects on TL and cancer risk, as well as 
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the time-varying nature of TL, pose challenges for interpreting MR estimates of the causal effect 
(74). However, while genetic instruments do not recapitulate all aspects of telomere function and 
dynamics, they can still provide a valid test of the causal hypothesis that inherited predisposition to 
telomere maintenance increases lung cancer susceptibility (75). Secondly, genetic instruments for 
leukocyte TL may not be accurate proxies for TL in target tissues, which would reduce the power of 
our genetic instruments. However, the validity of instruments based on leukocyte TL is supported by 
correlation between TL in leukocytes and other tissues, including lung, and comparable rates of 
telomere shortening across somatic tissues (76-78). Thirdly, our MR analysis may be affected by 
winner's curse, with the magnitude and strength of association with TL observed in the discovery 
dataset likely to be exaggerated, particularly the 5p15.33 instrument. However, since the instrument 
discovery and MR analysis populations are independent, any potential bias in the causal parameter 
due to winner’s curse or limited instrument strength will be towards the null (79). A related concern 
involves our ability to detect subtle effects of TL on cancer risk due to the modest proportion of 
variation in TL explained by our genetic instruments (approximately 5%), which is comparable to 
most genetic instruments for complex phenotypes (80-82). Based on our power calculations, this 
analysis was adequately powered (>80%) to detect effects with OR of 1.5 and above for all lung 
and HNC histological subtypes and smoking-stratified analyses.  
Lastly, the validity of our mediation analysis depends in part on the validity of the published 
estimates of the mediator-outcome relationship. MR-based estimates of the mediator-outcome 
relationship are likely to satisfy the assumption of no unmeasured confounding, but must assume 
that all instruments used in Zhang et al. (22) were valid. While observational studies are more 
susceptible to confounding and bias due measurement error in the molecular mediator (83), a 
synthesis of prospective studies provides complementary evidence that does not depend on MR 
assumptions, and is less vulnerable to reverse causation than case-control designs.  
In summary, we demonstrated that genetic determinants of long telomeres are associated 
with an increased risk of lung cancer, particularly adenocarcinoma. The associations observed for 
HNC were less consistent with a causal relationship, however we cannot preclude the possibility of 
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a very subtle telomere effects (OR<1.5). Using mediation analysis that incorporates independent 
published data, we validated the novel 5p15.33 instrument and quantified the proportion of the lung 
cancer association signal in 5p15.33 that is mediated by TL. While this work provides insight into 
the role of TL in cancer etiology, further research is needed to identify appropriate ways of utilizing 
this complex biomarker in the context of disease prevention or clinical intervention. 
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Table 1: Characteristics of the Toronto (MSH-PMH) and Copenhagen (CGPS) OncoArray studies that 
comprise the dataset for the development of genetic instruments for telomere length in chromosome 
5p15.33  
Characteristic and description 
Toronto      
(MSH-PMH) 
Copenhagen 
(CGPS) 
Total 
N (%) N (%) N (%) 
Age (years) 
<50  135 (17.4) 287 (24.5) 422 (20.6 
50 to 59 241 (28.6) 259 (22.1) 500 (24.4) 
60 to 69  313 (35.0) 264 (22.5) 577 (28.1) 
70 to 79 143 (14.7) 237 (20.2) 380 (18.5) 
≥80 47 (4.3) 125 (10.7) 172 (8.4) 
Mean (SD) 61.0 (11.7) 61.3 (12.8) 61.2 (12.3) 
Sex 
Males 436 (49.6) 470 (40.1) 906 (44.2) 
Females 443 (50.4) 702 (59.9) 1145 (55.8) 
Smoking 
status  
Never smokers 438 (50.1) 410 (36.4) 848 (41.3) 
Ever smokers 436 (49.6) 717 (61.2) 1153 (56.2) 
Former smokers 366 (41.7) 717 (61.2) 1083 (52.8) 
Current smokers 59 (6.7) 0 (0) 59 (2.9) 
Unknown 5 (0.6) 45 (3.8) 50 (2.4) 
Mean cigarette pack-years (SD) 8.7 (17.2) 14.4 (20.2) 12.0 (19.2) 
Total  879  1172  2051 (100.0) 
 
Abbreviations: 
CGPS Copenhagen General Population Study 
MSH-PMH Mount Sinai Hospital-Princess Margaret Hospital study 
SD Standard deviation 
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Table 2: Genetic variants included in the novel 5p15.33 instrumental variable and their associations with 
the telomere length Z-score in the combined dataset (n=2051)  
Variant Gene 
Alleles 
EAF 
Per-allele estimate 
P-value 
Long TL Other β
a,b
 (SE) 
rs956942 LINC01511 A G 2.4×10
-3
 1.11 (0.29) 1.7×10
-4
 
Chr5:1383486 CLPTM1L-SLC6A3 A G 4.9×10
-4
 2.09 (0.65) 1.4×10
-3
 
Chr5:1404329 SLC6A3 T C 9.8×10
-4
 1.28 (0.46) 5.8×10
-3
 
Chr5:1501109 LPCAT1 A G 7.4×10
-4
 1.46 (0.53) 6.1×10
-3
 
Chr5:1297379 TERT A C/G 1.5×10
-3
 0.68 (0.27) 0.01 
rs80022192 LINC01511 G A 4.9×10
-4
 1.60 (0.65) 0.01 
rs35033501 TERT A G 0.03 0.22 (0.09) 0.01 
rs28363089 SLC6A3 A G 0.03 0.23 (0.02) 0.01 
Chr5:1434327 SLC6A3 A T 0.99 0.89 (0.38) 0.02 
Chr5:1402812 SLC6A3 T C 4.9×10
-4
 1.49 (0.65) 0.02 
rs79717857 CLPTM1L A C 0.02 0.21 (0.09) 0.02 
rs35334674 TERT G A 0.97 0.19 (0.08) 0.02 
rs7733853 LPCAT1 A G 0.24 0.08 (0.03) 0.02 
rs72715516 SLC6A3 G A 0.96 0.21 (0.10) 0.04 
 
Abbreviations: 
 
EAF Effect allele frequency, where the effect allele is the long telomere allele 
 
SE Standard error 
 
LINC01511 Long intergenic non-protein coding RNA 1511 
 
CLPTM1L Cleft lip and palate associated transmembrane protein 1-like 
 
SLC6A3 Solute carrier family 6 member 3 
 
LPCAT1 Lysophosphatidylcholine acyltransferase 1 
 
TERT Telomerase reverse transcriptase 
a 
Linear regression models adjusted for age, sex, study, and ethnicity principal components 
b 
Regression coefficients are standardized and correspond to a 1 standard deviation (1 unit) change in 
the telomere length Z-score, approximately 1000 base pairs 
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Table 3: Per-allele associations for the 5p15.33 genetic instrument and relevant telomere and cancer 
endpoints 
Outcome 
Sample size 
(Cases, Controls) 
β
a 
/ OR
b
 (SE) / 95% CI P-value F statistic R
2
 (%) 
Telomere Length  2051 0.14 (0.02) 2.6×10
-9
 35.83 1.49 
Telomere length in never smokers  848 0.18  (0.04) 7.0×10
-6
 20.81 2.02 
Smoking status (ever/never)  2051 -0.08 (0.06) 0.19 - - 
Cigarette pack-years  1101 0.40 (0.73) 0.59 0.29 0.00 
Lung cancer  16396 13013 1.04 1.01, 1.07 4.89×10
-3
 - - 
Adenocarcinoma 5690 13013 1.06 1.03, 1.10 1.4×10
-3
 - - 
Squamous cell carcinoma 4045 13013 1.03 0.98, 1.07 0.23 - - 
Head and neck cancer 4415 5013 0.95 0.90, 1.00 0.04 - - 
Oral cavity 2284 5013 0.93 0.87, 0.98 0.01 - - 
Oropharynx 1849 5013 0.96 0.90, 1.03 0.26 - - 
Never smokers        
Lung cancer 1619 3923 1.06 0.99, 1.14 0.08 - - 
Adenocarcinoma  836 3923 1.12 1.02, 1.22 0.02 - - 
Head and neck cancer  773 1827 0.85 0.77, 0.95 3.8×10
-3
 - - 
Alcohol non-drinkers        
Head and neck cancer 614 795 0.86 0.74, 0.99 0.04 - - 
 
Abbreviations: 
 
R
2
 
Coefficient of determination estimating the proportion of the variance in the telomere 
length Z-score that is explained by the 5p15.33 genetic instrument  
 
SE Standard error 
 
TL Telomere length 
a 
Linear regression models were adjusted for age, sex, study, and top 5 ethnicity principal components 
b 
Logistic regression models were adjusted for age, sex, study, and top 10 ethnicity principal 
components 
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Table 4: Mendelian Randomization estimates of the causal odds ratios for lung and head and neck 
cancers per 1000 base pair increase in telomere length 
Outcome Cases Controls 
Estimation Method 
Maximum Likelihood Inverse Variance Weighted Weighted Median Estimator 
OR
a
 95% CI P-value OR
a
 95% CI P-value OR
a
 95% CI P-value 
Lung cancer 16396 13013 1.41 1.20, 1.65 2.0×10
-5
 1.39 1.21, 1.60 3.7×10
-6
 1.37 1.12, 1.67 2.0×10
-3
 
Adenocarcinoma 5690 13013 1.92 1.51, 2.45 1.3×10
-7
 1.83 1.51, 2.22 5.5×10
-10
 1.63 1.23, 2.16 6.5×10
-4
 
Squamous  4045 13013 1.04 0.83, 1.29 0.74 1.04 0.83, 1.29 0.74 1.09 0.82, 1.46 0.57 
Small cell  1846 13013 1.03 0.76, 1.39 0.86 1.03 0.76, 1.38 0.86 0.96 0.66, 1.38 0.82 
Head and neck cancer 4415 5013 0.90 0.70, 1.15 0.39 0.90 0.70, 1.15 0.41 0.71 0.51, 0.98 0.04 
Oral cavity 2284 5013 0.88 0.65, 1.19 0.40 0.88 0.65, 1.19 0.40 0.67 0.44, 1.03 0.07 
Oropharynx 1849 5013 0.83 0.59, 1.16 0.28 0.83 0.60, 1.16 0.28 0.72 0.46, 1.12 0.14 
Ever smokers            
Lung cancer 14498 8815 1.36 1.14, 1.63 5.3×10
-4
 1.36 1.15, 1.60 2.6×10
-4
 1.31 1.05, 1.63 0.02 
Adenocarcinoma 4754 8815 1.72 1.33, 2.24 4.2×10
-5
 1.66 1.33, 2.07 5.2×10
-6
 1.71 1.26, 2.32 6.1×10
-4
 
Squamous  3835 8815 1.06 0.84, 1.35 0.60 1.06 0.84, 1.35 0.61 1.08 0.80, 1.47 0.63 
Head and neck 3108 2865 1.12 0.79, 1.58 0.54 1.11 0.79, 1.56 0.54 0.91 0.60, 1.39 0.69 
Never smokers            
Lung cancer 1619 3923 1.78 1.22, 2.61 3.1×10
-3
 1.76 1.23, 2.52 2.0×10
-3
 1.55 0.98, 2.46 0.06 
Adenocarcinoma 836 3923 2.68 1.70, 4.24 2.4×10
-5
 2.68 1.70, 4.24 2.4×10
-5
 2.24 1.18, 4.27 0.01 
Squamous  149 3923 0.72 0.26, 1.97 0.52 0.72 0.26, 1.95 0.51 0.80 0.22, 2.90 0.75 
Head and neck  773 1827 0.72 0.42, 1.22 0.22 0.72 0.42, 1.22 0.22 0.71 0.32, 1.55 0.39 
Early onset (≤50 years)           
Lung cancer 1868 1557 1.68 1.07, 2.62 0.02 1.67 1.08, 2.59 0.02 1.76 0.98, 3.22 0.06 
Alcohol non-drinkers            
Head and neck 614 795 0.76 0.37, 1.56 0.45 0.76 0.37, 1.57 0.46 0.45 0.17, 1.16 0.10 
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Abbreviations: 
 
CI Confidence Intervals 
 
OR Odds ratio 
a 
Regression models for each genetic instrument were adjusted for age, sex, study, and the top 10 
ethnicity principal components 
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Figure 1: Conceptual diagram of Mendelian Randomization and mediation analyses. Mendelian 
Randomization is based the following assumptions (1–3): the genetic variant is strongly associated with 
telomere length; there is no direct association between the instrument and cancer outcome, except through 
telomere length; the genetic instrument is independent of any confounders (C). Mediation analyses of the 
5p15.33 instrument for telomere length and 5p15.33 susceptibility variants test for the presence of direct 
effects (4), and quantify how much of the total genetic effect on lung cancer risk is mediated by telomere 
length  
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Figure 2: Scatter plots showing the association estimates for telomere length (βTL) and cancer risk (βY)  for 
each instrumental variable  (IV), overlaid on the causal log odds ratio  for  the  effect of increasing telomere 
length on cancer risk (solid red line) and corresponding 95% confidence intervals (dotted red lines), 
estimated using the likelihood-based method  
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Figure 3: Odds ratio (OR) plot summarizing the direct effects (triangle, dotted line) and indirect effects 
(circle, solid line) of the 5p15.33 genetic instrument on lung cancer risk. Estimates of the direct and indirect 
effects are presented across different levels of interaction and for different versions of the mediator 
(dichotomous and continuous), indicated by different colours.  
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